Participating in a clinical trial is an important and personal decision. Thank you for considering the MagnetisMM-9 trial.

This trial is looking for about 119 participants with relapsed/refractory multiple myeloma. Among other things, participants in this trial must have tried but not had success with their most recent multiple myeloma therapy and at least one of each of the following treatments:

• Proteasome inhibitor (PI)
• Immunomodulatory drug (IMiD)
• Anti-CD38 monoclonal antibody (mAb)

If you are not sure which treatments you have received, please ask your doctor.

If you’re interested in participating, you will review and sign the informed consent document and continue with the screening process to confirm whether you’ve met all eligibility criteria. The screening period will take up to 28 days, including at least 1 visit to the study location.

The treatment period begins after screening, where you will stay in the hospital two to three times so that your health can be monitored by the trial team.

For the first six months, you will be asked to see the trial doctor every week or every other week to receive injections and complete various health assessments, which then may be adjusted.

You will receive the study medicines(s) until your condition progresses, you experience unmanageable side effects, or you choose to stop receiving the study medicine(s).

Approximately one month after your last dose, there will be one follow-up visit so the study team can observe your health and safety. Then, you will be contacted by phone about once every three months (or you may have a visit) to check on your health.

The total length of treatment will vary depending on how you tolerate and how your disease responds to the study medicine. Even if you stop taking the study medicine, you will be asked to stay in the study for at least two years.